Moreover, other LRRK2 mutations (e.g., LRRK2 R1441G/C/H mutations) and other kinases with increased activity deserve further investigation and are crucial for assessing the generalizability of DUSP6 therapy in PD. The gene discussed is DUSP6; the disease is Parkinson disease.